The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

Manette A.W. Dinnessen, Otto Visser, Sanne H. Tonino, Marjolein W.M. Poel, Nicole M.A. Blijlevens, Marie José Kersten, Pieternella J. Lugtenburg, Avinash G. Dinmohamed

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)


We assessed the impact of a prior malignancy diagnosis (PMD) – as a potential proxy for genetic cancer susceptibility – on the development of a second primary malignancy (SPM) and mortality in follicular lymphoma (FL) patients. From the nationwide Netherlands Cancer Registry, we selected all adult FL patients diagnosed in 1994-2012 (n = 8028) and PMDs and SPMs relative to FL, with follow-up until 2017. We constructed two Fine and Gray models – with death as a competing risk – to assess the association between a PMD and SPM incidence. A PMD was associated with an increased incidence of SPMs (subdistribution hazard ratio [SHR], 1.30; 95% confidence interval [CI], 1.03-1.64) – especially carcinomas of the respiratory tract (SHR, 1.83; 95% CI, 1.10-3.05) and cutaneous squamous cell carcinomas (SHR, 1.58; 95% CI, 1.01-2.45) – and a higher risk of mortality in a multivariable model (HR, 1.43; 95% CI, 1.19-1.71). However, when additionally adjusted for the receipt of systemic therapy and/or radiotherapy before FL diagnosis, only patients who received such therapies had an increased incidence of SPMs (SHR, 1.40; 95% CI, 1.02-1.93). In conclusion, patients with a PMD had a higher rate of SPMs and mortality than those without a PMD, which might have resulted from therapy-related carcinogenesis.
Original languageUndefined/Unknown
Pages (from-to)489-497
Issue number2
Publication statusPublished - 8 Oct 2020

Cite this